24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
Pandemic Has More Americans Turning to BoozeStudy Confirms Minorities Face Higher Odds of COVID-19: StudyLockdown Could Worsen Hearing Woes for U.S. SeniorsWarming World Could Alter West Nile Transmission in U.S.Most Newborns of COVID-19-Infected Moms Fare WellCOVID Antibodies Found in Less Than 10% of AmericansCOVID-19 Patients Rarely Survive Cardiac Arrest: StudyLow Vitamin D Levels Tied to Higher Odds for Severe COVIDKids Much Less Prone to Coronavirus Infection Than Adults: Study'Silent' COVID-19 Produces as Much Virus as in Patients With Symptoms: StudyImmune System Clues to Why COVID Is Easier on KidsU.S. Coronavirus Cases Top 7 MillionAccuracy of COVID-19 Antibody Tests Varies Widely, Study FindsAmerica's COVID Pandemic Is Now Skewing YoungerEven If Hips, Legs Slim Down, Belly Fat Remains a Health DangerAfter COVID-19 Exposure, When Can Young Athletes Resume Play?Kids Who Need Steroids Face Risk of Diabetes, Other Ills9 in 10 Americans Not Yet Immune to COVID, CDC Director SaysCommon Heart Defect Limits Exercise Ability: StudyBlood Test Could Spot Those at Highest Risk for Severe COVID-19Singing Without a Face Mask Can Spread COVID-19Could Zinc Help Fight COVID-19?U.S. COVID Death Toll Hits 200,000 as Cases Climb in 22 States4 Out of 5 People With COVID-19 Will Develop Symptoms: StudyMany Health Care Workers Who Have Coronavirus Don't Have Symptoms: StudyAHA News: Cluster of Risky Conditions That Can Lead To Heart Disease Is Rising in Hispanic AdultsMinorities Hit Hardest When COVID Strikes Nursing HomesAvoid the 'Twindemic:' Get Your Flu Shot NowCertain Cancer Treatments May Heighten Danger From COVID-19Homemade Masks Do a Great Job Blocking COVID-19Having Flu and COVID Doubles Death Risk in Hospitalized PatientsGuard Yourself Against the Health Dangers of Wildfire SmokeLife Expectancy Could Decline Worldwide Due to COVID-19Potential COVID-19 Drug Could Increase Heart Risk: StudyU.S. COVID Death Toll Nears 200,000, While Cases Start to Climb AgainCDC Reverses COVID Test Guideline After ControversyAs Schools Reopen, Many Students, Staff Live With High-Risk Family MemberCOVID-19 Poses Added Risk for People With Addiction Disorders: StudyGetting a Hip Replacement? Choice of Hospital Can Be CrucialAlmost 90,000 Young American Adults Will Get Cancer This Year: ReportAnother Rapid COVID-19 Test Shows PromiseDetails Emerge on Unexplained Illness in AstraZeneca COVID Vaccine TrialRising Obesity Levels Put Americans at Risk During Pandemic: CDCMore Pets May Be Getting COVID-19 Than RealizedWildfire Smoke Poses Special Threat to People With AsthmaCOVID-19 Prevention Might Translate Into Record Low Flu Rates: CDCFor Stroke Survivors, Timely Rehab Has Been Jeopardized During PandemicCOVID-19 Has Taken a Toll on Organ DonationCOVID Conflicts Are Putting Big Strains on RelationshipsCoronavirus Vaccine Plan for Americans Announced
Questions and AnswersLinks
Related Topics

Diabetes

Could the First Drug That Slows Arthritis Be Here?

HealthDay News
by By Amy NortonHealthDay Reporter
Updated: Aug 3rd 2020

new article illustration

MONDAY, Aug. 3, 2020 (HealthDay News) -- There are currently no medications that can slow down the common form of arthritis that strikes aging knees and hips. But a new study suggests a powerful, and expensive, anti-inflammatory drug could potentially do just that.

The drug, called canakinumab (Ilaris), is used for certain rare rheumatic conditions marked by widespread inflammation. They include juvenile idiopathic arthritis, where the immune system mistakenly attacks the lining of the joints.

The new findings suggest the drug might hold promise for easing the highly common type of arthritis that sets in with age: osteoarthritis.

The researchers found that among 10,000 patients given canakinumab in a clinical trial, the risk of having a knee or hip replacement was cut by at least 40% over four years. Those surgeries are generally done to treat severe osteoarthritis.

However, the trial -- funded by Ilaris-maker Novartis -- has a major limitation: It was not actually designed to test the drug for osteoarthritis. Instead, researchers wanted to know if it could prevent heart attacks in high-risk people.

The reduction in joint replacements was a fortuitous finding.

"We're hoping that this will stimulate further research," said Dr. Paul Ridker, the senior researcher on the study. "These data derive from a very large trial, and they're pointing to a potential new pathway in the treatment of osteoarthritis."

Canakinumab works by blocking interleukin-1 beta (IL-1β) -- a chemical produced by the immune system that helps regulate the body's inflammatory response. Recent studies have pointed to a role for IL-1β in the inflammation that marks osteoarthritis.

"Back when I was in medical school, we learned that rheumatoid arthritis was an inflammatory condition and osteoarthritis was 'wear-and-tear,'" said Ridker, of Harvard Medical School and Brigham and Women's Hospital, in Boston.

But, he said, the wear-and-tear concept is untrue, as osteoarthritis does seem to involve systemic inflammation.

In fact, a few small clinical trials have tested various IL-1 inhibitors for easing the pain of knee osteoarthritis. And they've come up empty.

But that, Ridker said, may simply be because the trials were too small and too short-term.

Dr. Nancy Lane, a professor and arthritis researcher at the University of California, Davis, agreed.

She praised the new study as "groundbreaking." Even though the trial did not directly test canakinumab for arthritis, Lane said, the reduction in joint replacements is major.

"Right now, we have no treatments that prevent osteoarthritis or slow its progression," Lane said.

At this point, she stressed, it's not clear that canakinumab actually does slow joint degeneration. It's possible it reduced people's pain, which can delay hip or knee replacements.

So that's one of the questions for future research, Lane said.

Lane co-wrote an editorial accompanying the study, which was published online Aug. 3 in the Annals of Internal Medicine.

The findings are based on a clinical trial that enrolled more than 10,000 people who'd suffered a heart attack. The hope was to cut the risk of a repeat heart attack by giving them canakinumab along with standard medications. Half of the patients were randomly assigned to take the drug, while the other half used a placebo.

Canakinumab was taken by injection, once every three months.

Ridker's team found that over roughly four years, patients on the drug were 40% to 47% less likely to need joint replacement surgery, versus the placebo group.

There was one key element to the trial: All patients had elevated blood levels of C-reactive protein (CRP). Ridker said this is a marker of chronic, low-grade inflammation in the body.

According to Lane, that raises an interesting possibility. Maybe there is a group of arthritis patients -- those with high CRP -- who are more likely to benefit from canakinumab.

Because the drug inhibits an immune system chemical, the main risk is that it can leave people more vulnerable to serious infections. In the heart disease trial, patients given canakinumab had a somewhat lower heart attack risk, but they also had a higher rate of fatal infections -- though the risk was low overall.

If canakinumab is proven to prevent joint replacements, there will be a practical issue -- the drug's huge price tag, at thousands of dollars per injection. In 2018, the U.S. Food and Drug Administration rejected Novartis's bid to have canakinumab approved for heart disease; some cardiology experts had concluded the benefit was too small to justify expanding its use.

More information

The Arthritis Foundation has more on osteoarthritis.